ResMed Tops Profit Estimates and Names New CFO
The medical device maker reported adjusted quarterly profit of $2.86 per share on strong demand. Aaron Bloomer was named CFO as the firm downplayed GLP-1 risks.
Xurve View
洞察:
Xurve View
RESMED INC reported adjusted profit of $2.86 per share for the quarter ending March 31, beating LSEG estimates of $2.80. Quarterly revenue rose 11% to $1.43 billion, surpassing Wall Street expectations of $1.42 billion. ResMed is positioning GLP-1 weight-loss drugs as a tailwind for diagnosis rather than a threat to device demand.
